New hope for AL amyloidosis: teclistamab trial targets stubborn disease

NCT ID NCT06649695

Recruiting now Disease control Sponsor: European Myeloma Network B.V. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 31 times

Summary

This study tests a drug called teclistamab in 30 adults with AL amyloidosis that has not responded well to previous treatments. The goal is to see if the drug can reduce or eliminate the abnormal proteins causing organ damage. Participants will receive teclistamab and be monitored for response and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU Limoges
RECRUITING

Limoges, France

Contact
Fondazione I.R.C.C.S Policlinico "San Matteo"
RECRUITING

Pavia, Italy

Contact
General Hospital of Athens "Alexandra"
RECRUITING

Athens, Greece

Contact
Paris St Louis
NOT_YET_RECRUITING

Paris, France

Contact
South Australia Health
RECRUITING

Adelaide, Australia

Contact
UMC Utrecht
RECRUITING

Utrecht, Netherlands

Contact
University Hospital Essen
RECRUITING

Essen, Germany

Contact
University Hospital Heidelberg
RECRUITING

Heidelberg, Germany

Contact
University Hospital Würzburg
RECRUITING

Würzburg, Germany

Contact
Westmead Hospital
RECRUITING

Sydney, Australia

Contact

Conditions

Explore the condition pages connected to this study.

AL AMYLOIDOSIS AL AMYLOIDOSIS